Last update: Jan. 15, 2020
Minimal risk for breastfeeding and infant.
A macrolide with actions and uses very similar to erythromycin.
Indicated in respiratory infections, mycobacterial infections and in gastric and duodenal ulcers associated with Helicobacter pylori.
Administered orally twice daily.
It is excreted in breastmilk in very small amounts (Sedlmayr 1993). 12% of infants whose mothers were taking it had mild side effects such as gastroenteritis or drowsiness (Goldstein 2009).
It is an antibiotic commonly used in pediatrics.
Various medical associations and expert consensus consider it safe to use this medication during breastfeeding (Hale 2019, Briggs 2017, Butler 2014, Schaefer 2007, Goldstein 2009, Mahadevan 2006, Bar-Oz 2003, Chin 2001).
Some authors have linked direct and early exposure (first 15 days of life) to macrolides (especially erythromycin) with hypertrophic pyloric stenosis (Almaramhy 2019, Lund 2014) and also through breastmilk (Maheshwai 2007, Sorensen 2003, Stang 1986) but others have not (Almaramhy 2019, Abdellatif 2019, Goldstein 2009) or not for macrolides which are different to erythromycin (Maheshwai 2007).
The possibility of transient gastroenteritis due to altered intestinal flora in infants whose mothers take antibiotics should be taken into account (Goldstein 2009, Ito 1993).
We do not have alternatives for Clarithromycin since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana from Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM